Has Jeffrey Suh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $223,334 in general payments to Jeffrey Suh, MD across 278 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Suh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Suh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Suh, MD

Otolaryngology · Los Angeles, CANPI 1114172442

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $171,488 of the $223,334 with a category attached, or 76.8%. Stryker accounts for 77.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $49,922 and has fallen 51.2% since, to $24,383 in 2025. Among otolaryngology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$223,334in general payments, 2019–2025

Across 278 payments — averaging $803.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Stryker$173K
Medtronic$18K
Baxter Healthcare$11K
KARL Storz Endoscopy-america$6K
Smith+Nephew$6K
Sanofi$3K
plus $7K from 16 others

$5,959in research payments, 2019–2025

Across 2 payments — averaging $2979.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$6K

What the payments were for

Consulting fees$171,48877%
Speaking & faculty fees$27,43312%
Travel & lodging$11,8875%
Food & beverage$12,5276%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Stryker	137	$172,556
Medtronic(2 entities)	30	$18,366
Baxter Healthcare	10	$11,293
KARL Storz Endoscopy-america	10	$5,895
Smith+Nephew	16	$5,543
Sanofi	5	$2,759
Aerin Medical Inc.	22	$2,299
Acclarent, Inc	12	$1,074
Optinose US, Inc.	7	$800
Intersect ENT, Inc.	9	$750
Neurent Medical Limited	3	$457
Regeneron	3	$299
AstraZeneca	2	$211
Regeneron Healthcare Solutions, Inc.	2	$200
3-d Matrix, Inc.	1	$174
BD	2	$138
Integra Lifesciences Corporation	1	$129
GSK	1	$110
Novartis	1	$101
Johnson & Johnson	1	$100
Amgen	2	$55
Cook Medical LLC	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

HEMOPORE$46,125
SCOPIS ENT$39,545
XPRESS ENT DILATION SYSTEM$26,174
CORE$25,765
CLARIFIX CRYOTHERAPY DEVICE$20,086
SHAVER SYSTEM$18,875
N/A$18,226
SONOPET IQ$17,500
LATERA$14,266
ENTELLUS - XPRESS ENT DILATION SYSTEM$13,433
NSE - HIGH SPEED DRILLS$12,843
TGS GUIDEWIRE$9,134
PREVELEAK$8,894
FUSION$8,162
NASOPORE$5,500
REFLEX ULTRA Turbinate Wands$5,064
XPRESS LOPROFILE$3,625
DUPIXENT$3,003
STEALTHSTATION S8 PLATFORM$2,565
PUNCH, FRONTAL , SINUS$2,000

How this compares

$223,334 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California →

Medicare billing

Part B allowed, 2024

$261,354

Medicare patients

266

Services billed

1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluticasone Propionate	86	$1,278
Ipratropium Bromide	42	$882
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	34	$538
Ciprofloxacin Hcl	23	$256
Omeprazole	13	$173
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	37	$158
Mupirocin	16	$105
Prednisone	17	$63

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Los Angeles

Keith BlackwellLos Angeles$349K
Dennis TangLos Angeles$209K
Elisabeth FerenceLos Angeles$111K
Arthur WuLos Angeles$67K
Richard MichelinLos Angeles$57K
Maie St JohnLos Angeles$39K
Kevin GrafmillerLos Angeles$27K
Philip KnottLos Angeles$24K
Uttam SinhaLos Angeles$18K
Joni DohertyLos Angeles$16K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →